• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Allakos Inc (NQ: ALLK )

    0.6793 -0.0337 (-4.73%)
    Streaming Delayed Price Updated: 2:25 PM EDT, Aug 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Allakos Inc

    < Previous 1 2 3 4 5 Next >
    ALLK Stock Earnings: Allakos Beats EPS for Q2 2024
    ALLK stock results show that Allakos beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
    From Allakos Inc.
    Via GlobeNewswire
    Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
    From Allakos Inc.
    Via GlobeNewswire
    Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
    From Allakos Inc.
    Via GlobeNewswire
    ALLK Stock Earnings: Allakos Meets EPS for Q1 2024
    ALLK stock results show that Allakos met analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    ALLK Stock Earnings: Allakos Misses EPS for Q4 2023
    ALLK stock results show that Allakos missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Where Allakos Stands With Analysts
    Via Benzinga
    Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
    From Allakos Inc.
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Pre-market stock movers are worth checking out this morning as we dive into all of the biggest news moving shares on Friday! 
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning! 
    Via InvestorPlace
    What 4 Analyst Ratings Have To Say About Allakos
    Via Benzinga
    3 Biotech Stocks to Dump Before They Go to Zero
    These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling. 
    Via InvestorPlace
    Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    From Allakos Inc.
    Via GlobeNewswire
    Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
    From Allakos Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
    From Allakos Inc.
    Via GlobeNewswire
    Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Gold Down 1%; PNC Financial Posts Upbeat Earnings
    U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 350 points on Tuesday. The Dow traded down 0.93% to 37,243.85 while the NASDAQ fell 0.58% to 14,885.45. The... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Crude Oil Edges Lower; Morgan Stanley Posts Upbeat Revenue
    U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling more than 150 points on Tuesday. The Dow traded down 0.46% to 37,421.80 while the NASDAQ fell 0.02% to... 
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Why Is Allakos (ALLK) Stock Down 57% Today?
    Allakos stock is falling hard on Tuesday as investors in ALLK react to two of the company's Phase 2 clinical trials failing. 
    Via InvestorPlace
    Trial Setback: Allakos Drops Lead Skin Disorder Candidate, Cuts Workforce By 50%
    Allakos reports disappointing topline data from phase 2 trials for lirentelimab in atopic dermatitis and chronic spontaneous urticaria. Company undergoes restructuring to focus on AK006, extending cash... 
    Via Benzinga
    Dow Dips 200 Points; Goldman Sachs Earnings Top Views
    U.S. stocks traded lower this morning, with the Dow Jones index falling more than 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.56% to 37,384.20 while the NASDAQ... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Allakos Announces a Restructuring to Focus on Development of AK006
    From Allakos Inc.
    Via GlobeNewswire
    Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
    From Allakos Inc.
    Via GlobeNewswire
    Allakos Analyst Turns Bullish, Sees 'Significant Upside' If Study Results Are Positive
    Shares of Allakos Inc (NASDAQ: ALLK) were climbing in early trading on Monday. 
    Via Benzinga
    Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
    From Allakos Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.